Drugs in early clinical development for the treatment of female sexual dysfunction

Bibliography

• Berman L, Bermans J, Chhabra S, Goldstein I. Novel approaches to female sexual dysfunction. Expert Opin Investig Drugs 2001;10(1):85–95
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Rezaee RL. Hypoactive sexual desire in women. Menopause 2013;20(12):1284-300
   PubMed Web of Science ®Google Scholar
• Davison SL, Bell RJ, LaChina M, et al. ORIGINAL RESEARCH—PSYCHOLOGY: the relationship between Self‐Reported sexual satisfaction and general Well‐Being in women. J Sex Med 2009;6(10):2690-7
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edition. American Psychiatric Publishing; Arlington, VA: 2013
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. Text rev 2000. 10.1176/appi.books.9780890423349
   Google Scholar
• Leiblum SR, Koochaki PE, Rodenberg CA, et al. Hypoactive sexual desire disorder in postmenopausal women: US results from the women’s international study of health and sexuality (WISHeS). Menopause 2006;13(1):46-56
   PubMed Web of Science ®Google Scholar
• Hayes RD, Bennett CM, Fairley CK, Dennerstein L. Original Research—Epidemiology: what can prevalence studies tell us about female sexual difficulty and dysfunction? The Journal of Sexual Medicine 2006;3(4):589-95
   PubMed Web of Science ®Google Scholar
• Simons J, Carey M. Prevalence of sexual dysfunctions. Arch Sex Behav 2001;30(2):177-219
   PubMed Web of Science ®Google Scholar
• Kingsberg S, Rezaee R. Hypoactive sexual desire in women. [Review]. Menopause 2013;20(12):1284-300
   PubMed Web of Science ®Google Scholar
• Perelman M. The sexual tipping point: a mind/model for sexual medicine. J Sex Med 2009;6:629-32
   PubMed Web of Science ®Google Scholar
• Salonia A, Giraldi A, Chivers ML, et al. Physiology of women’s sexual function: basic knowledge and new findings. J Sex Med 2010;7(8):2637-60
   PubMed Web of Science ®Google Scholar
• Islam A, Mitchel J, Rosen R, et al. Topical alprostadil in the treatment of female sexual arousal disorder: a pilot study. J Sex Marital Ther 2001;27:531-40
   PubMed Web of Science ®Google Scholar
• Gittelman M, Costabile R, Peterson C, et al. In-clinic evaluation of the safety and efficacy of topical alprostadil (PGE1) for the treatment of female sexual arousal disorder (abstract). Presented at: 97th Annual Meeting of the American Urological Association; 25-30 March 2002; Orlando, FL
   Google Scholar
• Kielbasa L, Daniel K. Topical alprostadil treatment of female sexual arousal disorder. Ann Pharmacother 2006;40:1369-76
   PubMed Web of Science ®Google Scholar
• Goldstein I, Qinping L, Damaj B, et al. Phase 3 clinical trial results with femprox treatment in FSAD patients show correlation of arousal with both lubrication and orgasm but not with desire. J Sex Med 2013;10(2):164
   Google Scholar
• Giraldi A, Rellini AH, Pfaus J, Laan E. Female sexual arousal disorders. J Sex Med 2013;10(1):58-73
   PubMed Web of Science ®Google Scholar
• Portman DJ, Edelson J, Jordan R, et al. Bremelanotide for hypoactive sexual desire disorder: Analyses from a phase 2B dose-ranging study. Obstet Gynecol 2014(Suppl 1):31S
   Google Scholar
• Jordan R, Edelson J, Greenberg S, et al. Efficacy of subcutaneous bremelanotide self-administered at home by premenopausal women with female sexual dysfunction: a placebo-controlled dose-ranging study. J Sex Med 2013;10(Suppl 2):178
   Google Scholar
• Portman DJ1, Edelson J, Jordan R, et al. Bremelanotide for hypoactive sexual desire disorder: Analyses from a phase 2b dose-ranging study. Obstet Gynecol 2014;123(Suppl 1):31S
   Google Scholar
• Sand M, Fisher WA. Women’s endorsement of models of female sexual response: the nurses’ sexuality study. J Sex Med 2007;4:708-19
   PubMed Web of Science ®Google Scholar
• Krychman M, Kingsberg S. Female sexual disorders: treatment options in the pipeline. Formulary Journal.Com 2013;48
   Google Scholar
• Tkachenko N, Dickstein J, Kreppner W. An open-label, single and multiple-application of intranasal testosterone gel (TBS-2) in healthy pre-menopausal female subjects at three dose levels. J Sex Med 2013;10(Suppl 2):165
   Google Scholar
• van Gorsel H, Laan E, Tkachenko N, et al. Pharmacokinetics and pharmacodynamic efficacy of testosterone intranasal gel in women with hypoactive sexual desire disorder and anorgasmia. J Sex Med 2012
   Web of Science ®Google Scholar
• Laan E, Nievaard M, Tkachenko N, et al. Randomized, placebo controlled, five-arm parallel group study to assess efficacy of TBS-2 intranasal gel using vibrotactile stimulation combined with visual sexual stimulation in women in anorgasmia. J Sex Med 2013;10:165-6
   Web of Science ®Google Scholar
• Panjari M, Davis S. DHEA for postmenopausal women: a review of the evidence. Maturitas 2010;66:172-9
   PubMed Web of Science ®Google Scholar
• Panjari M, Davis SR. Vaginal DHEA to treat menopause related atrophy: a review of the evidence. Maturitas 2011;70(1):22-5
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer D, Bouchard C, et al. Effect of intravaginal dehydroepiandrosterone (prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009;15(5):923-31
   Google Scholar
• Labrie F, Archer D, Bouchard C, et al. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause 2009;16(5):897-906
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer D, Bouchard C, et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric 2011;14:282-8
   PubMed Web of Science ®Google Scholar
• Labrie F, Martel C, Berube R, et al. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentration of estrogens or androgens. J Steroid Biochem Mol Biol 2013;138:359-67
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer D, Bouchard C, et al. Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. J Sex Med 2014;11(7):1766-85
   PubMed Web of Science ®Google Scholar
• Bloemers J, van Rooij K, Poels S, et al. Toward personalized sexual medicine (part 1): integrating the “dual control model” into differential drug treatments for hypoactive sexual desire disorder and female sexual arousal disorder. J Sex Med 2013;10(3):791-809
   PubMed Web of Science ®Google Scholar
• Poels S, Bloemers J, van Rooij K, et al. Toward personalized sexual medicine (part 2): testosterone combined with a PDE5 inhibitor increases sexual satisfaction in women with HSDD and FSAD, and a low sensitive system for sexual cues. J Sex Med 2013;10(3):810-23
   PubMed Web of Science ®Google Scholar
• Poels S, Bloemers J, van Rooij K, et al. Two novel combined drug treatments for women with hypoactive sexual desire disorder. Pharmacol Biochem Behav 2014;121(0):71-9
   PubMedGoogle Scholar
• van Rooij K, Poels S, Bloemers J, et al. Toward personalized sexual medicine (part 3): testosterone combined with a Serotonin1A receptor agonist increases sexual satisfaction in women with HSDD and FSAD, and dysfunctional activation of sexual inhibitory mechanisms. J Sex Med 2013;10(3):824-37
   PubMed Web of Science ®Google Scholar
• van Rooij K1, de Leede L, Frijlink HW, et al. Pharmacokinetics of a prototype formulation of sublingual testosterone and a buspirone tablet, versus an advanced combination tablet of testosterone and buspirone in healthy premenopausal women. Drugs R D2014;14(2):125-32
   PubMedGoogle Scholar
• Yang L. MPOA lesions affect female pacing of copulation in rats. Behav Neurosci 2000;6:1191-202
   Google Scholar
• Caruso S. Nonhormonal treatment options for female sexual dysfunction. In: Goldstein I, Meston CM, Davis S, Traish A, editors. Women’s sexual function and dysfunction: study, diagnosis and treatment. CRC Press; 2005
   Google Scholar
• Beharry RK, Hale TM, Wilson EA. Evidence for centrally initiated genital vasocongestive engorgement in the female rat: findings from a new model of female sexual arousal response. Int J Impot Res 2003;15(2):122-8
   PubMed Web of Science ®Google Scholar
• Tarcan T, Siroky MB, Park K. Systemic administration of apomorphine improves the hemodynamic mechanism of clitoral and vaginal engorgement in the rabbit. Int J Impot Res 2000;12(4):235-40
   PubMed Web of Science ®Google Scholar
• Bechara A, Bertolino MV, Casabé A, Fredotovich N. Original Research: central Mechanism Therapy for FSD: a double-blind randomized placebo control study comparing the objective and subjective changes in female sexual response using sublingual apomorphine. J Sex Med 2004;1(2):209-14
   PubMed Web of Science ®Google Scholar
• Caruso S, Agnello C, Intelisano G, et al. Placebo-controlled study on efficacy and safety of daily apomorphine SL intake in premenopausal women affected by hypoactive sexual desire disorder and sexual arousal disorder. Urology 2004;63(5):955-9
   PubMed Web of Science ®Google Scholar
• Bergner D. There may be a pill for that. The New York Times Magazine. The New York Times; New York: 2013. p. 22-49
   Google Scholar
• Bancroft J, Graham C, Janssen E, Sanders S. The dual control model: current status and future directions. J Sex Research 2009;46:121-42
   PubMed Web of Science ®Google Scholar
• Silverman E. Is the FDA Sexist? Regulators Pressed to OK for Female Sexual Problems. Available from: http://blogs.wsj.com/pharmalot/2014/07/08/is-the-fda-sexist-regulators-pressed-to-ok-drugs-for-female-sex-problems/
   Google Scholar